what is the mechanism of action of glp-1 agonists Glucagon-like peptide-1 Possible mechanisms of action of

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)

Migraines and Obesity Obesity was associated with a 27% increased risk of migraine with the association being particularly strong in women and younger individuals, according to a meta-analysis by Gelaye et al

GLP-1s for weight loss account for more than 10% of annual prescription drug claims for employer-based plans that reimburse them, according to recent data

Nat Rev Neurosci 15:367378 Son JW, Kim S (2020) Comprehensive Review of Current and Upcoming Anti-Obesity Drugs